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Abstract
Background—Global dietary recommendations for and cardiovascular effects of linoleic acid, 
the major dietary omega-6 fatty acid, and its major metabolite, arachidonic acid, remain 
controversial. To address this uncertainty and inform international recommendations, we evaluated 
how in vivo circulating and tissue levels of linoleic acid (LA) and arachidonic acid (AA) relate to 
incident cardiovascular disease (CVD) across multiple international studies.
Methods—We performed harmonized, de novo, individual-level analyses in a global consortium 
of 30 prospective observational studies from 13 countries. Multivariable-adjusted associations of 
circulating and adipose tissue LA and AA biomarkers with incident total CVD and subtypes 
(coronary heart disease (CHD), ischemic stroke, cardiovascular mortality) were investigated 
according to a prespecified analytical plan. Levels of LA and AA, measured as % of total fatty 
acids, were evaluated linearly according to their interquintile range (i.e., the range between the 
mid-point of the first and fifth quintiles), and categorically by quintiles. Study-specific results 
were pooled using inverse-variance weighted meta-analysis. Heterogeneity was explored by age, 
sex, race, diabetes, statin use, aspirin use, omega-3 levels, and fatty acid desaturase 1 genotype 
(when available).
Results—In 30 prospective studies with medians of follow-up ranging 2.5 to 31.9 years, 15,198 
incident cardiovascular events occurred among 68,659 participants. Higher levels of LA were 
significantly associated with lower risks of total CVD, cardiovascular mortality, and ischemic 
stroke, with hazard ratios per interquintile range of 0.93 (95% CI: 0.88–0.99), 0.78 (0.70–0.85), 
and 0.88 (0.79–0.98), respectively, and nonsignificantly with lower CHD risk (0.94; 0.88–1.00). 
Relationships were similar for LA evaluated across quintiles. AA levels were not associated with 
higher risk of cardiovascular outcomes; comparing extreme quintiles, higher levels were 
associated with lower risk of total CVD (0.92; 0.86–0.99). No consistent heterogeneity by 
population subgroups was identified in the observed relationships.
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Conclusions—In pooled global analyses, higher in vivo circulating and tissue levels of LA and 
possibly AA were associated with lower risk of major cardiovascular events. These results support 
a favorable role for LA in CVD prevention.
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INTRODUCTION
Recommendations for dietary consumption omega-6 (n-6) polyunsaturated fatty acids 
(PUFA) for cardiovascular disease (CVD) prevention remain controversial and inconsistent.1 
For example, the American Heart Association and the Academy of Nutrition and Dietetics 
recommend 5–10%,1, 2 the United Nations Food and Agriculture Organization recommends 
2.5–9%,3 while the French national guidelines recommend 4%.4 Pooled evidence from 
clinical trials and cohort studies suggests a moderate benefit of consuming n-6 PUFA, 
predominantly linoleic acid (LA, 18:2n-6), for coronary heart disease (CHD) risk, whether 
replacing saturated fat or total carbohydrate.5–7 In contrast, recent secondary analyses of 
clinical trials of LA-rich corn oil (although not LA-rich soybean oil) conducted in the 
1960s-1970s suggest a possible increased risk of overall and CHD mortality.8, 9 The 
interpretation of these latter trials is hampered by their short duration,8, 9 small numbers of 
events,8 substantial drop-out,9 and confounding by industrial trans-fats.8, 9 In addition, many 
of the other prior trials are limited by lack of blinding or randomization, and major dietary 
pattern shifts; and most are decades old, creating potentially low generalizability to 
contemporary diets and clinical settings. Cohort studies are limited by the common reliance 
on self-reported dietary habits, which can be influenced by memory errors and inaccurate 
nutrient databases. Thus, for many scientists, clinicians, and policy makers, the role of LA in 
CVD risk remains uncertain.
In addition, concerns have been raised that n-6 PUFA could actually increase CVD risk, due 
to potential pro-inflammatory effects.9, 10 LA is a precursor of the n-6 PUFA arachidonic 
acid (AA, 20:4n-6), which gives rise to a range of eicosanoids considered to be pro-
inflammatory and pro-thrombotic.10, 11Yet, stable isotope studies suggest very limited 
conversion of LA to AA in humans,12 and trials show limited effects of increasing dietary 
LA on plasma and adipose tissue AA levels.12–14 These findings indicate the importance of 
directly evaluating AA levels instead of inferring them from LA levels or intakes in relation 
to CVD risk. As LA cannot be produced endogenously (making tissue levels reasonable 
markers of intake), biomarker (circulating and adipose tissue) levels correlate with dietary 
consumption.15, 16 Such objective biomarkers allow evaluation of dietary exposure of LA 
status independent of self-reported food habits and estimated nutrient composition of 
different foods. Circulating and adipose biomarkers also allow direct evaluation of AA, 
which is highly metabolically regulated and for which dietary estimates correlate poorly 
with in vivo levels.
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Yet, the relations between in vivo levels of LA and AA and CHD risk have been evaluated in 
relatively few studies, with different study designs, outcomes, exposures (e.g., lipid 
compartment), covariates, and statistical methodology. Results from meta-analyses of 
published studies using circulating or adipose tissue levels of n-6 PUFA have been 
contradictory.17, 18 Furthermore, associations between in vivo n-6 PUFA levels and other 
CVD outcomes including stroke, total CVD, and CVD mortality have been studied less 
frequently19–23 and remain uncertain.
To address these major gaps in knowledge, we conducted a pooled analysis of harmonized, 
de novo, individual-level data across 30 cohort studies in the Fatty Acid and Outcome 
Research Consortium (FORCE) to evaluate associations of LA and AA levels with incident 
total CVD and subtypes (CHD, ischemic stroke, CVD mortality).
METHODS
Data Availability
The institutional review board approvals and data sharing agreements for the participating 
cohorts allowed us to share cohort results. Individual participant data are owned by 
individual participating cohorts and are available to researchers consented from participating 
cohorts. For further queries or requests, please contact force@tufts.edu. Further details are 
available at the FORCE website: http://force.nutrition.tufts.edu/.
Study setting and population: FORCE Consortium
The study was conducted within FORCE (http://force.nutrition.tufts.edu), a consortium of 
studies with circulating or adipose tissue fatty acid biomarker measurements and ascertained 
chronic disease events.24 Studies were identified and invited to participate if assessing 
biomarker (circulating or adipose tissue) levels of LA and AA, and incident CVD (or 
subtypes thereof), based on previous FORCE projects,24, 25 expert contacts, and online 
searches. Studies with adult participants (≥18 y) free of CVD (myocardial infarction, angina, 
coronary revascularization, stroke) at the time of fatty acid sampling were invited. 
Retrospective case-control studies were included in a sensitivity analysis if fatty acids were 
assessed in adipose tissue, which have a long half-life of exposure.26 To minimize potential 
reverse causation, the main analysis included only prospective studies. Of 38 studies invited 
by September 2017, 31 participated (Table 1 and Supplemental Tables 1–2 in the online-only 
Data Supplement), while 7 were ineligible, declined to participate, or failed to respond 
(Supplemental Table 3 in the online-only Data Supplement). The study was approved by the 
institutional review boards of the participating cohorts.
Fatty acid measurements
Studies measured fatty acids in differing compartments, including plasma phospholipids, 
erythrocytes, plasma, serum, cholesterol esters, and adipose tissue. All fatty acid levels were 
reported as percent of total fatty acids. Detailed information regarding fatty acid 
measurements in each study is provided in the Supplemental Material.
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Outcome assessment
In each cohort, study participants were excluded if they were children (age <18 years) or had 
prevalent CVD at the time of fatty acid measurement. Among the remaining participants, we 
evaluated incident CVD (defined as incident CHD or stroke) and its subtypes including 
CHD (fatal or nonfatal myocardial infarction, CHD death, or sudden cardiac death), 
ischemic stroke (fatal or nonfatal ischemic stroke), and CVD mortality (the subset of fatal 
events from these causes). Studies that did not separately assess ischemic stroke used total 
stroke (n=5 studies). Detailed information on outcomes in each study is provided in the 
Supplemental Material.
Covariates
To minimize potential confounding, prespecified and harmonized covariates were utilized 
included age (years), sex (male/female), race (Caucasian/non-Caucasian, or study-specific), 
field center if applicable (categories), body-mass index (BMI, kg/m2), education (less than 
high school graduate, high school graduate, some college or vocational school, college 
graduate), smoking (current, former, never; if history not assessed, then current/not current), 
physical activity (quintiles of metabolic equivalents (METs)/week), alcohol intake (none, 1–
6 drinks/week, 1–2 drinks/day, >2 drinks/day), prevalent diabetes mellitus (defined as 
treatment with oral antihyperglycemic agents, insulin, or fasting plasma glucose >126 mg/
dL), treated hypertension (defined as hypertension drug use; or if unavailable, as diagnosed/
history of hypertension), treated hypercholesterolemia (defined as LDL-lowering drug use; if 
unavailable, as diagnosed/history of hypercholesterolemia), regular aspirin use (defined as 
≥2 times/week), levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 
20:5n-3), sum of trans isomers of oleic acid (trans18:1), and sum of trans isomers of LA 
(trans-18:2) (each expressed as % total FAs). If data did not allow such categorization, 
study-specific categories were used. Imputation was allowed for linear covariates if 
previously established in each cohort; missing indicator categories were utilized for missing 
covariate data in categories.
Statistical analysis and pooling
All participating studies followed a prespecified, harmonized analysis protocol with 
standardized exclusions, exposures, outcomes, covariates, and analytical methods. In each 
study, de novo analyses of individual data were performed according to the protocol. Cox 
and weighted Cox proportional hazards models were used to estimate hazard ratios in cohort 
and nested unmatched case-cohort studies, respectively, with follow-up from the date of 
blood or adipose tissue sampling to date of incident event, death, loss to follow-up, or end of 
follow-up. In matched nested case-control studies, conditional logistic regression was used 
to estimate odds-ratios for each outcome, considered to approximate hazard ratios. To assess 
potential nonlinear associations, each cohort also evaluated study-specific quintiles as 
indicator categories, with the lowest quintile as the reference. Studies assessing fatty acids in 
multiple compartments conducted separate analyses in each compartment. To investigate 
potential heterogeneity by other factors, associations in each study were also assessed in 
prespecified strata by age, sex, race, ALA and EPA levels, prevalent diabetes, drug-treated 
hypercholesterolemia, and regular aspirin use. Potential interactions by genotype were 
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examined in the 14 studies with available data for rs174547 (single nucleotide 
polymorphism in the gene for fatty acid desaturase 1, a major genetic determinant of 
circulating LA and AA).27 Interaction terms were constructed as a cross-product of LA or 
AA and rs174547 (as an additive effect: 0, 1, or 2 T-alleles) and included with the main 
effects in the models. Robust variance was used in all analyses.
Results from each study were provided to the lead author in standardized electronic forms 
and pooled using inverse-variance weighted meta-analysis. The results were pooled overall 
and within each specific type of fatty acid compartment including phospholipids 
(erythrocyte phospholipids or plasma phospholipids), total plasma, cholesterol esters, and 
adipose tissue. To allow comparison and pooling of results across different compartments, 
LA and AA concentrations were standardized to study-specific interquintile range defined as 
the range between the midpoint of the first and fifth quintiles (i.e., range between 10th and 
90th percentiles). Potential semi-parametric associations were assessed by meta-regression 
with restricted cubic splines constructed from study-specific quintiles.28
Overall heterogeneity was assessed by the I2-statistic, with values of ~ 25%, 50%, and 75%, 
considered to indicate low, medium, and high heterogeneity, respectively.29 Heterogeneity 
between prespecified subgroups was explored by meta-analyzing study-specific effect 
estimates from each stratum, with statistical differences between subgroups tested by meta-
regression. Potential interactions by desaturase genotype were examined by meta-analyzing 
study-specific interaction terms. For each study, associations of n-6 PUFA with CVD per 
genotype at rs174547 (i.e, CC, CT, or TT) were calculated from beta coefficients and the 
variance-covariance matrix of the main and interaction terms.24 The genotype-specific 
estimates were pooled using pooled using inverse-variance weighted meta-analysis. While 
subgroups were prespecified, all heterogeneity analyses were considered exploratory and 
Bonferroni-corrected for multiple comparisons (10 subgroups; corrected α=0.005).
In sensitivity analyses, we evaluated compartment-specific associations using absolute 
percent of total fatty acids as the unit of exposure, instead of study-specific interquintile 
range. In other sensitivity analyses, we censored events at maximum 10 y of follow-up, to 
minimize bias by changes in fatty acid levels over time; used alternative blood compartments 
in the overall pooled analysis for studies having more than one measure; included one 
retrospective study; and excluded studies assessing only fatal outcomes.
Meta-analyses were performed using Stata 13 (StataCorp, College Station, TX), with two-
tailed α=0.05 for the primary analyses.
RESULTS
The pooled analyses included 76,356 fatty acid measurements from 68,659 participants in 
30 prospective studies from 13 countries (Table 1). The studies included 18 cohort and 12 
nested case-control or case-cohort studies. Most studies assessed fatty acids in blood 
compartments (plasma phospholipids, n=11 studies; erythrocyte phospholipids, total plasma, 
or cholesterol esters, n=7 studies each), while adipose tissue was less commonly used (n=3 
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studies). One retrospective case-control study measuring adipose tissue biomarkers was 
included in a sensitivity analysis, but not in the primary analyses.
Across studies, mean age at baseline ranged from 49 to 77 years (Table 1 and Supplemental 
Table 4). Overall proportions of women and men were comparable, although some studies 
included one sex only (Table 1). Most participants were Caucasian, but several studies 
included sizable numbers of African Americans, Asians, and Hispanics (Supplemental Table 
5). In most studies, up to 30% of the participants smoked, and alcohol intake was generally 
moderate (<1 drink/d). Education level, diabetes prevalence, and medication use varied 
across studies. As would be expected, levels of fatty acids varied between different 
compartments (Figure 1 and Supplemental Tables 4 and 6).
Median study follow-up durations ranged from 2.5 to 31.9 years. Among the 30 prospective 
studies, 10,477 total incident CVD events, 4,508 CVD deaths, 11,857 incident CHD events, 
and 3,705 incident ischemic strokes occurred (Supplemental Table 7).
Per interquintile range, higher LA levels were associated with 7% (95%CI: 1–12%), 22% 
(15–30%), and 12% (2–21%) lower incidence of total CVD, CVD mortality, and ischemic 
stroke, respectively (Figures 2–3, Table 2). LA levels were also nonsignificantly (P=0.065) 
associated with lower incidence of total CHD. Overall heterogeneity was moderate (I2=28–
63%). Associations of LA with total CVD, total CHD, and CVD mortality varied by 
compartment (P-interaction≤0.031), with generally less prominent inverse associations in 
studies utilizing phospholipids (Figures 2–3).
Compared to the lowest quintile, participants in the highest quintile of LA levels experienced 
lower risk of CVD mortality (HR=0.77; 95% CI, 0.69–0.86), with nonsignificant trends 
toward lower risk of total CVD (0.94; 0.87–1.01), CHD (0.92; 0.85–1.00), and ischemic 
stroke (0.90; 0.79–1.02) (Supplemental Table 8). There was no significant evidence of non-
linear associations between LA and each outcome (P-nonlinearity>0.05 each).
AA levels evaluated linearly were not significantly associated with CVD events, with a 
hazard ratio of 0.95 (0.90–1.01) for total CVD (Table 2, Figures 4–5). When different lipid 
compartments were assessed, AA levels in total plasma, but not other compartments, were 
associated with lower risk of total CVD (HR=0.81 (0.70–0.94) (Table 2, Figure 4). Overall 
heterogeneity was low to moderate (I2≤54%). When AA levels were evaluated in quintiles 
(Supplemental Table 9), participants in the highest quintile, compared to the lowest, 
experienced significantly lower incidence of total CVD (0.92; 0.86–0.99). There was 
evidence for a borderline nonlinear association (P-nonlinearity=0.039) between total plasma 
AA and ischemic stroke (Supplemental Figure 1).
Associations of LA and AA with CVD outcomes did not significantly differ according to 
subgroups defined by age, sex, race, n-3 PUFA levels, diabetes status, statin use, aspirin use, 
or baseline year of fatty acid measurement (Supplemental Table 10). In 14 studies with 
genotype data (Supplemental Table 11), a significant interaction (P-interaction=0.002) was 
observed between LA and rs174547 genotype in relation to risk of ischemic stroke 
(Supplemental Table 12), with inverse associations appearing stronger in carriers of the 
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major T-allele. The associations of AA with cardiovascular outcomes did not significantly 
vary by rs174547 genotype.
In sensitivity analyses, results of compartment-specific analysis that utilized units of percent 
of total fatty acids, rather than study-specific interquintile ranges, were not appreciably 
different from the main findings (Supplemental Table 13). Results were also similar across 
all other sensitivity analyses (Supplemental Table 14).
DISCUSSION
In this harmonized, individual-level pooled analysis across 30 prospective studies from 13 
countries, higher in vivo levels of the n-6 PUFA LA were associated with lower risk of CVD 
events, in particular CVD mortality and stroke. AA levels were not associated with higher 
risk, and were associated with lower CVD risk in some analyses. To our knowledge, this is 
the largest pooled analysis of fatty acid levels and CVD endpoints, including almost 70,000 
individuals and 10,000 total CVD events.
Our findings provide evidence to help inform currently inconsistent global dietary 
recommendations on n-6 PUFA consumption. LA, an essential fatty acid not synthesized by 
humans, is the main dietary PUFA, comprising about 85–90% of the total. While circulating 
and adipose tissue LA levels can be influenced by metabolism,27, 30 they are established and 
useful markers of diet as they increase in a dose-response manner in response to dietary LA 
in controlled feeding trials15, 26, 30 and consistently correlate with self-reported dietary 
estimates in large cohort studies,26 including a considerable number of studies participating 
in the current analysis (Supplemental Table 15). Several lines of evidence support 
mechanisms by which dietary LA may reduce CVD. In randomized controlled feeding trials, 
dietary PUFA (primarily LA) as a replacement for either carbohydrates or saturated fat 
lowers low density lipoprotein (LDL)-cholesterol, triglycerides, and ApoB levels, and raises 
high density lipoprotein (HDL)-cholesterol;14, 31 and also lowers hemoglobin A1c and 
insulin resistance and potentially augments insulin production.32 Other potential 
cardiometabolic benefits of dietary LA may include favorable effects on inflammation,14 
blood pressure,33 and body composition, including prevention and reduction of visceral and 
liver fat.14, 34 In a pooled analyses of prospective cohort studies, self-reported estimates of 
LA consumption are associated with lower CHD risk.6 Similarly, in meta-analyses of older, 
limited clinical trials, increased consumption of LA-rich vegetable oils, especially soybean 
oil, reduces the risk of CHD.5 Our findings evaluating in vivo levels of LA status across 
multiple global studies add strong support for cardiovascular benefits of LA.
While AA has long been considered an archetypical pro-inflammatory and pro-thrombotic 
fatty acid, growing evidence suggests its effects may be more complex.35 In the present 
investigation, AA levels were not associated with higher risk of CVD, and indeed in some 
analyses were associated with lower risk. These results do not provide support for adverse 
cardiovascular effects of AA. While AA is the precursor to potentially pro-inflammatory 
leukotrienes, it is also the main precursor to key anti-inflammatory metabolites, such as 
epoxyeicosatrienoic acids and prostaglandin E2, as well as other mediators that actively 
resolve inflammation, such as lipoxin A4.35 It also gives rise to prostacyclin, a potent anti-
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aggregatory and vasodilatory molecule.36 These complex biologic effects preclude simplistic 
inference on health effects of AA metabolites and further support the importance of empiric 
assessment of relationships with clinical events, such as in our investigation.
Overall, our findings provide little support for the hypothesis that LA or AA, the major n-6 
PUFA, may increase CVD risk. We also identified little evidence for any interaction between 
n-6 and n-3 PUFA levels, consistent with prior reviews of dietary data.1 n-6 PUFA may also 
have additional metabolic benefits. For example, a recent pooled analysis from FORCE 
identified a strong inverse association of circulating and adipose tissue LA levels and 
incidence of type 2 diabetes, with no significant associations for AA.25 Taken together with 
results of randomized controlled feeding trials of blood lipids, glucose-insulin homeostasis, 
and other metabolic risk factors; prospective cohort studies of self-reported consumption; 
and (older, methodologically limited) clinical trials of LA-rich plant oils, our novel findings 
do not support recommendations of some10 to reduce n-6 PUFA consumption or reduce the 
n-6:n-3 ratio (as opposed to increasing n-3 intake). Rather, the findings from the present 
study, together with the prior research summarized above, support independent 
cardioprotective benefits of LA.
Our results provide important evidence that helps inform clinical and population 
recommendations. Dietary guidelines from several organizations, including the American 
Heart Association, recommend increased consumption of n-6 PUFA to prevent CVD.7 
However, some researchers9, 10, 37 and other national guidelines4 currently recommend 
avoidance of n-6 PUFA and reductions from current intake levels. Furthermore, current 
trends in oil production are leading to increased use of high-oleic, LA-depleted seed oils,38 
which can increase the risk of insufficient PUFA consumption in population subgroups. Our 
findings, combined with prior evidence from metabolic feeding trials, supports 
cardiovascular benefits of LA and a need to harmonize international guidelines and priorities 
for oilseed production and use.
A unique strength of our investigation was the ability to assess associations across distinct 
lipid compartments across which LA (AA) levels intercorrelate to varying degrees (e.g., 
r=0.4–0.9),26, 39, 40 suggesting that each compartment reflects partly differing metabolic and 
physiologic influences. Yet, our findings were generally concordant across compartments, 
providing support for common or similar biologic effects of these n-6 fatty acids across 
these compartments.
The inverse association of LA levels with ischemic stroke was more pronounced in T-allele 
carriers of rs174547, a polymorphism in FADS1 associated with higher fatty acid desaturase 
activities27, 41 and FADS1 expression.42 Although located in FADS1, rs174547 is also in 
strong linkage disequilibrium with polymorphisms in FADS2 (encoding the LA-desaturating 
FADS2) and has emerged as the main genetic determinant of circulating LA and AA in a 
recent genome-wide association study.27 The T-allele has been linked to several metabolic 
traits including higher cholesterol (total, LDL, and HDL)43 and fasting glucose44, but also 
lower triglycerides43 and heart rate.45 The pleiotropy of the FADS cluster and the specificity 
for ischemic stroke rather than all CVD endpoints complicates the interpretation of the 
observed gene-LA interaction, which should therefore be viewed cautiously. Yet, one could 
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also speculate that carriers of the major T-allele derive greater benefits from the established 
LDL-lowering effects of dietary LA and thus have accentuated health benefits –a ripe area 
for further investigation.
Few prior meta-analyses of LA and AA levels in CVD have been performed. In one analysis 
of 10 published studies with 28,000 participants and 3,800 events, LA was not significantly 
associated with coronary events, while AA was associated with a 17% reduction in risk.18 In 
a meta-analysis of published studies acute myocardial infarction and coronary syndromes 
including many retrospective case-control studies, circulating and adipose tissue LA levels 
were inversely associated with the risk of CHD events, while overall associations for AA 
were null.17 Our investigation considerably extends these prior results by focusing on 
prospective studies, performing new individual-level study-specific analyses using a 
standardized and harmonized analysis protocol, including a much larger number of 
participants and events, and evaluating several major CVD outcomes. Importantly, our 
consortium also greatly minimizes publication bias by incorporating new (unpublished) 
findings from all available studies, rather than pooling only prior published results.
Other strengths include use of in vivo n-6 PUFA levels, which complement self-reported 
dietary estimates, reduce errors from memory, and allow assessment of biologically relevant 
in vivo levels-especially important for AA. Outcomes in nearly all studies were defined by 
centralized adjudication processes or validated registries rather than from self-report alone, 
reducing the potential for missed or misclassified endpoints. Inclusion of cohorts from 13 
countries across several continents enhances generalizability. The large numbers of 
participants and events allowed us to explore several potential effect modifiers and the shape 
of the associations.
Potential limitations deserve attention. For certain compartments, such as adipose tissue, few 
studies were available. Most individuals were of European descent, lowering statistical 
power for evaluating other races/ethnicities. Despite extensive efforts to harmonize study-
specific methods, some dissimilarities remained between cohorts in outcome definitions (see 
Expanded Methods in the Supplemental Material) and covariate categorization 
(Supplemental Table 5). Although such variety and unmeasured background population 
characteristics may increase generalizability, these may also have contributed to the 
moderate between-study heterogeneity observed for some exposure-outcome relationships. 
Fatty acids were measured once at baseline, and changes over time could lead to 
misclassification, which would attenuate the associations. However, reasonable temporal 
reproducibility has been reported for LA and AA concentrations over time.46 Since few 
studies evaluated multiple compartments, and because cholesterol esters were only assessed 
by studies from Northern Europe, we were hampered in drawing any conclusions of true 
predictive differences between lipid fractions. Although fatty acid analytical methods were 
not standardized across studies, the use of a quintile-based statistical approach minimizes 
this concern. We did not adjust for non-fatty acid dietary factors, but pooling results across 
multiple cohorts with different population characteristics increases the validity of the 
findings. While all studies consistently adjusted for other major CVD risk factors, we cannot 
exclude residual confounding due to unmeasured or imprecisely measured covariates. 
However, the concordance of the present observed associations with other lines of evidence 
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on cardiovascular benefits of LA1, 5, 6, 32 provide biologic plausibility for our findings. We 
did not evaluate the associations after exclusion of early cases. However, such sensitivity did 
not produce results substantially different from the main findings in our previous pooling 
projects24, 25 and in cohort-specific analyses,23 suggesting that the observed associations are 
not likely due to reverse causation.
In summary, based on pooled individual-level analyses of prospective studies, circulating 
and adipose tissue biomarker concentrations of LA were inversely associated with CVD 
while AA was not associated with higher CVD risk. Together with prior research, these 
results support CVD benefits of LA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Clinical perspective
What is new?
• We conducted the hitherto largest pooled individual-level analysis using 
circulating and adipose tissue levels of linoleic acid and arachidonic acid to 
examine the link between omega-6 fatty acids and cardiovascular outcomes in 
various populations.
• Our approach increases statistical power and generalizability compared to 
individual studies; lowers the risk of publication bias and heterogeneity 
compared to meta-analyses of existing literature; and allows evaluation of the 
associations in key population subgroups.
• Strikingly, higher level of linoleic acid was associated with lower risks of total 
cardiovascular disease, ischemic stroke, and cardiovascular mortality, while 
arachidonic acid was not associated with cardiovascular risk.
What are the clinical implications?
• Our findings support potential benefits of the main dietary omega-6 fatty acid, 
i.e., linoleic acid, for cardiovascular disease prevention.
• Furthermore, our results do not support any theorized cardiovascular harms of 
omega-6 fatty acids.
• Our findings provide evidence to help inform currently inconsistent global 
dietary recommendations on omega-6 consumption.
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Figure 1. Concentration of A) linoleic acid (LA; 18:2n6) and B) arachidonic acid (AA; 20:4n6) 
across different biomarker compartments measured in the 31 contributing studies.
Concentrations of arachidonic acid and linoleic acid concentrations are expressed as % of 
total fatty acids (FA), and indicated as median (circles) and interquintile range (lines; 
defined as the range between the midpoint of the bottom quintile [10th percentile] and the 
top quintile [90th percentile]), respectively. For MPCDRF and the MORGEN, values are 
only shown for controls.*Total number of individual FA measured in the biomarker 
compartment. †Not reported.
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Figure 2. Associations of linoleic acid (LA; 18:2n6) with total CVD (A) and CVD mortality (B) in 
pooled analysis of 30 prospective studies.
Study-specific estimates for hazard ratio (HR) per interquintile range (i.e., range between the 
midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) of 
biomarker linoleic acid were pooled based on the following order: 1) adipose tissue, 2) 
erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 5) total plasma. 
Study weights are indicated (grey squares) by individual biomarker compartment and 
overall. Study-specific analyses were conducted using models that included the following 
covariates: age (years), sex (male/female), race (Caucasian/non-Caucasian, or study-
specific), field center if applicable (categories), body-mass index (BMI, kg/m2), education 
(less than high school graduate, high school graduate, some college or vocational school, 
college graduate), smoking (current, former, never; if history not assessed, then current/not 
current), physical activity (quintiles of metabolic equivalents (METs)/week), alcohol intake 
(none, 1–6 drinks/week, 1–2 drinks/day, >2 drinks/day), prevalent diabetes mellitus (defined 
as treatment with oral antihyperglycemic agents, insulin, or fasting plasma glucose >126 mg/
dL), treated hypertension (defined as hypertension drug use; or if unavailable, as diagnosed/
history of hypertension), treated hypercholesterolemia (defined as LDL-lowering drug use; if 
unavailable, as diagnosed/history of hypercholesterolemia), regular aspirin use (defined as 
≥2 times/week), levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 
20:5n-3), sum of trans isomers of oleic acid (trans18:1), and sum of trans isomers of LA 
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(trans-18:2) (each expressed as % total FAs). If data did not allow such categorization, 
study-specific categories were used. See Table 1 footnote for abbreviations of cohorts.
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Figure 3. Associations of linoleic acid (LA; 18:2n6) with total CHD (A) and ischemic stroke (B) in 
pooled analysis of 30 prospective studies.
Study-specific estimates for hazard ratio (HR) per interquintile range (i.e., range between the 
midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) of 
biomarker linoleic acid were pooled based on the following order: 1) adipose tissue, 2) 
erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 5) total plasma. 
Study weights are indicated (grey squares) by individual biomarker compartment and 
overall. Study-specific analyses were conducted using models that included the following 
covariates: age (years), sex (male/female), race (Caucasian/non-Caucasian, or study-
specific), field center if applicable (categories), body-mass index (BMI, kg/m2), education 
(less than high school graduate, high school graduate, some college or vocational school, 
college graduate), smoking (current, former, never; if history not assessed, then current/not 
current), physical activity (quintiles of metabolic equivalents (METs)/week), alcohol intake 
(none, 1–6 drinks/week, 1–2 drinks/day, >2 drinks/day), prevalent diabetes mellitus (defined 
as treatment with oral antihyperglycemic agents, insulin, or fasting plasma glucose >126 mg/
dL), treated hypertension (defined as hypertension drug use; or if unavailable, as diagnosed/
history of hypertension), treated hypercholesterolemia (defined as LDL-lowering drug use; if 
unavailable, as diagnosed/history of hypercholesterolemia), regular aspirin use (defined as 
≥2 times/week), levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 
20:5n-3), sum of trans isomers of oleic acid (trans18:1), and sum of trans isomers of LA 
(trans-18:2) (each expressed as % total FAs). If data did not allow such categorization, 
study-specific categories were used. See Table 1 footnote for abbreviations of cohorts.
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Figure 4. Associations of arachidonic acid (AA; 20:4n6) with total CVD (A) and CVD mortality 
(B) in pooled analysis of 30 prospective studies.
Study-specific estimates for hazard ratio (HR) per interquintile range (i.e., range between the 
midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) of 
biomarker linoleic acid were pooled based on the following order: 1) adipose tissue, 2) 
erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 5) total plasma. 
Study weights are indicated (grey squares) by individual biomarker compartment and 
overall. Study-specific analyses were conducted using models that included the following 
covariates: age (years), sex (male/female), race (Caucasian/non-Caucasian, or study-
specific), field center if applicable (categories), body-mass index (BMI, kg/m2), education 
(less than high school graduate, high school graduate, some college or vocational school, 
college graduate), smoking (current, former, never; if history not assessed, then current/not 
current), physical activity (quintiles of metabolic equivalents (METs)/week), alcohol intake 
(none, 1–6 drinks/week, 1–2 drinks/day, >2 drinks/day), prevalent diabetes mellitus (defined 
as treatment with oral antihyperglycemic agents, insulin, or fasting plasma glucose >126 mg/
dL), treated hypertension (defined as hypertension drug use; or if unavailable, as diagnosed/
history of hypertension), treated hypercholesterolemia (defined as LDL-lowering drug use; if 
unavailable, as diagnosed/history of hypercholesterolemia), regular aspirin use (defined as 
≥2 times/week), levels of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 
20:5n-3), sum of trans isomers of oleic acid (trans18:1), and sum of trans isomers of LA 
(trans-18:2) (each expressed as % total FAs). If data did not allow such categorization, 
study-specific categories were used. See Table 1 footnote for abbreviations of cohorts.
Marklund et al. Page 23
Circulation. Author manuscript; available in PMC 2020 May 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. Associations of arachidonic acid (AA; 20:4n6) with total CHD (A) and ischemic stroke 
(B) in pooled analysis of 30 prospective studies.
Study-specific estimates for hazard ratio (HR) per interquintile range (i.e., range between the 
midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) of 
biomarker linoleic acid were pooled based on the following order: 1) adipose tissue, 2) 
erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 5) total plasma. 
Study weights are indicated (grey squares) by individual biomarker compartment and 
overall. Study-specific analyses were conducted using models that included the following 
covariates: age (linear), sex (male/female), race (binary: Caucasian/non-Caucasian, or study-
specific), field or clinical center if applicable (study-specific categories), body-mass index 
(BMI, linear), education (less than high school graduate, high school graduate, some college 
or vocational school, college graduate), smoking (current, former, or never; if former not 
assessed, then current or not current), physical activity (quintiles of metabolic equivalents 
(METs) per week; or if METs unavailable, quintiles of study-specific definitions of physical 
or leisure activity), alcohol intake (none, 1–6 drinks/week, 1–2 drink/day, >2 drink/day [14 g 
alcohol=1 standard drink]), diabetes mellitus (yes or no; defined as treatment with oral 
hypoglycemic agents, insulin, or fasting plasma glucose >126 mg/dL), treated hypertension 
(yes or no; defined as hypertension drug use; or if unavailable, as diagnosed/history of 
hypertension according to study-specific definitions), treated hypercholesterolemia (yes or 
no; defined as lipid-lowering drug use; if unavailable, as diagnosed/history of 
hypercholesterolemia according to study-specific definitions), regular aspirin use (yes or 
no), biomarker concentrations of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid 
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(EPA; 20:5n-3), sum of trans-18:1 fatty acids, and sum of trans-18:2 fatty acids (all linear; 
expressed as % total fatty acids). If data did not allow such categorization, study-specific 
categories were used. See Table 1 footnote for abbreviations of cohorts.
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Table 2.
Risk of incident CVD according to objective biomarker levels of linoleic acid (18:2n6) and arachidonic acid 
(20:4n6) in 30 pooled prospective cohort studies
Multivariable-adjusted hazard ratio (95% CI)
per interquintile range†
Outcome Biomarker Studies (n) Cases (n) Linoleic acid Arachidonic acid
Total CVD Phospholipid 14 6 853 1.00 (0.92–1.09) 0.95 (0.87–1.03)
Total plasma 6 2 742 0.90 (0.78–1.03) 0.81 (0.70–0.94)
Cholesterol esters 4 1 300 0.74 (0.63–0.88) 1.03 (0.88–1.20)
Adipose tissue 2 1 412 0.87 (0.75–1.01) 0.98 (0.87–1.10)
Overall‡ 21 10 477 0.93 (0.88–0.99) 0.95 (0.90–1.01)
CVD mortality Phospholipid 9 3 057 0.89 (0.79–1.00) 0.93 (0.83–1.05)
Total plasma 4 679 0.66 (0.50–0.86) 0.85 (0.66–1.09)
Cholesterol esters 3 473 0.56 (0.43–0.73) 0.99 (0.76–1.29)
Adipose tissue 2 418 0.60 (0.44–0.82) 1.02 (0.84–1.23)
Overall‡ 17 4 508 0.78 (0.70–0.85) 0.94 (0.86–1.02)
Total CHD Phospholipid 14 6 075 1.01 (0.93–1.10) 0.96 (0.90–1.03)
Total plasma 7 2 430 0.86 (0.74–1.00) 0.86 (0.74–1.01)
Cholesterol esters 5 1 178 0.78 (0.65–0.94) 1.02 (0.85–1.23)
Adipose tissue 3§ 3 255 0.88 (0.74–1.03) 1.10 (0.98–1.23)
Overall‡ 26§ 11 857 0.94 (0.88–1.00) 0.99 (0.94–1.04)
Ischemic stroke Phospholipid 12 2 327 0.95 (0.82–1.10) 0.98 (0.85–1.13)
Total plasma 6 1 105 0.84 (0.66–1.06) 0.93 (0.73–1.18)
Cholesterol esters 4 598 0.67 (0.51–0.88) 1.13 (0.89–1.43)
Adipose tissue 2 405 0.87 (0.65–1.15) 0.91 (0.74–1.11)
Overall‡ 21 3 705 0.88 (0.79–0.98) 0.99 (0.90–1.10)
*AA, arachidonic acid; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; LA, linoleic acid.
†
Based on harmonized, de novo individual-level analyses in each cohort, pooled using inverse-variance weighted meta-analysis. Risk was assessed 
according to the interquintile range (i.e., range between the midpoint of the bottom quintile [10th percentile] and the top quintile [90th percentile]) 
of each fatty acid, corresponding to the difference between the midpoint of the first and fifth quintiless. Study-specific analyses were adjusted for 
age (years), sex (male/female), race (Caucasian/non-Caucasian, or study-specific), field or clinical center if applicable (study-specific categories), 
body-mass index (BMI, kg/m2), education (less than high school graduate, high school graduate, some college or vocational school, college 
graduate), smoking (current, former, or never; if former not assessed, then current or not current), physical activity (quintiles of metabolic 
equivalents (METs) per week; or if METs unavailable, quintiles of study-specific definitions of physical or leisure activity), alcohol intake (none, 
1–6 drinks/week, 1–2 drink/day, >2 drink/day [14 g alcohol=1 standard drink]), diabetes mellitus (yes/no; defined as treatment with oral 
hypoglycemic agents, insulin, or fasting plasma glucose >126 mg/dL), treated hypertension (yes/no; defined as hypertension drug use; or if 
unavailable, as diagnosed/history of hypertension according to study-specific definitions), treated hypercholesterolemia (yes or no; defined as lipid-
lowering drug use; if unavailable, as diagnosed/history of hypercholesterolemia according to study-specific definitions), regular aspirin use (yes/
no), biomarker concentrations of α-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3), sum of trans-18:1 fatty acids, and sum of 
trans-18:2 fatty acids (each expressed as % total fatty acids).
‡
For studies that assessed LA and AA levels in more than one biomarker compartment, the primary compartment for that study was pre-selected 
for pooled analyses based on the following order: 1) adipose tissue, 2) erythrocyte phospholipid, 3) plasma phospholipid 4) cholesterol ester, and 5) 
total plasma.
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§
Because the Diet, Cancer and Health study assessed associations of AA, but not LA, with total CHD (n cases=2138), a total of, 2 studies (n cases= 
1117) evaluated adipose tissue LA and 25 studies (n cases=9719) assessed any biomarker level of LA in relation to total CHD.
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